BrightPath Biotherapeutics Co., Ltd.

TSE:4594 Stock Report

Market Cap: JP¥4.6b

BrightPath Biotherapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Kenichi Nagai

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure15.8yrs
CEO ownership0.3%
Management average tenureno data
Board average tenure9.4yrs

Recent management updates

Recent updates

CEO

Kenichi Nagai (54 yo)

15.8yrs

Tenure

Mr. Kenichi Nagai has been the Chief Executive Officer of BrightPath Biotherapeutics Co., Ltd. (Formerly, GreenPeptide Co., Ltd.) since 2011. Mr. Nagai served as Chief Financial Officer and Manager of Admi...

Board Members

NamePositionTenureCompensationOwnership
Kenichi Nagai
CEO & Representative Director15.8yrsno data0.29%
¥ 13.4m
Yoichi Takeshita
CFO & Director1.4yrsno datano data
Norihiro Nakamura
GM of Drug Discovery Research Department & Director6.4yrsno datano data
Hirotaka Takeuchi
Independent External Director9.4yrsno datano data
Akira Yamada
Director20.8yrsno data0.22%
¥ 10.4m
Taketoshi Abe
External Auditor15.4yrsno datano data
Yoshiyasu Yamaguchi
External Auditor9.4yrsno datano data
Tsutomu Kishino
Internal Auditor5.8yrsno datano data

9.4yrs

Average Tenure

63.5yo

Average Age

Experienced Board: 4594's board of directors are considered experienced (9.4 years average tenure).